Thiogenesis Therapeutics Corporation
Tracked across 1 events · 6 articles · First seen Jun 01, 2026 · Last active Jun 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Thiogenesis Therapeutics Corporation, a clinical-stage biotechnology company, successfully completed an oversubscribed non-brokered private placement, raising gross proceeds of C$9,071,850. The company issued 18,143,700 common shares at C$0.50 per share. The funds will primarily be used…
Impact: Thiogenesis Therapeutics Corporation successfully completed an oversubscribed private placement, raising C$9.07 million, which will fund the clinical development of its drug TTI-0102 and other corporate purposes. This significantly improves its financial position and ability to advance its pipeline.
Jun 01, 2026 · 6 articles
100
Thiogenesis Therapeutics Corporation completed private placementThiogenesis Therapeutics...
60
Thiogenesis Therapeutics Corporation paid finder's feesThiogenesis Therapeutics...
50
TSX Venture Exchange gave conditional acceptance Thiogenesis Therapeutics CorporationThiogenesis Therapeutics...
40
Thiogenesis Therapeutics Corporation engaged as advisor Bloom Burton SecuritiesThiogenesis Therapeutics...
NEWSDESK
Track Thiogenesis Therapeutics Corporation live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard